Moderna has marked a significant milestone in the UK pharmaceuticals landscape by launching a £150m manufacturing and research facility in Oxfordshire. The ribbon-cutting ceremony, attended by Moderna’s chief executive Stéphane
Pharmaceutical3- Page
163Articles
Bristol Myers Squibb BMS has issued a pointed demand for the NHS to fund a greater share of pharmaceutical innovation calling for the UK to pay what it describes as
Novo Nordisk, headquartered in Copenhagen, has seen its shares surge by more than 6 per cent after unveiling promising results from a late-stage clinical trial of its new anti-obesity tablet.
GSK, one of Britain’s foremost pharmaceutical giants, has announced an ambitious plan to invest $30 billion in the United States over the coming five years. This investment will bolster research
The battle between the NHS and pharmaceutical giants is reaching boiling point as accusations fly over the UK’s approach to funding modern medicines. A fresh row has ignited during President
Dr Aseem Malhotra’s address at the recent Reform UK party conference in Birmingham sent ripples through the pharmaceutical sector and political circles alike. Known for his vocal opposition to Covid19
AstraZeneca, the United Kingdom’s most valuable listed business, has announced a pause on its planned £200 million expansion at the Cambridge research hub, dealing a substantial setback to the government’s
The United Kingdom is facing a stark decline in its attractiveness to global investors in the life sciences and pharmaceutical industries, with industry leaders warning the nation is falling behind
Merck, the renowned US pharmaceuticals giant known as MSD across Europe, has abandoned plans for a £1 billion research centre in London—a significant blow for the UK life sciences sector.
Denmark’s pharmaceutical powerhouse Novo Nordisk is set to axe 9000 jobs, marking one of the most substantial workforce reductions in its history, as the company battles a steeply declining share
The United Kingdom stands on the threshold of a radical transformation in obesity treatment, as Eli Lilly prepares to introduce a daily weight-loss pill, Orforglipron, in 2026, once regulatory approval
Eli Lilly, the US manufacturer of the weight management injection Mounjaro, has announced a new discount for private pharmacies in the UK. The move follows widespread concern after the company
Britain faces a growing crisis in its life sciences sector as a senior executive at Novartis has declared the UK “uninvestable” owing to stringent and outdated drug pricing policies. Johan
Eli Lilly, one of the world’s largest pharmaceutical companies, has temporarily halted orders of its highly sought-after weight-loss injection, Mounjaro, to the UK. This move comes as the market braces
Brussels and Washington have unveiled the specifics of a major EU-US trade agreement, delivering a considerable boon to Ireland’s pharmaceutical sector. Under the terms, the United States will impose a
Wes Streeting, the new health secretary, has escalated his confrontation with leading pharmaceutical firms over the soaring cost of medicines and its impact on the UK’s broader life sciences sector.
